Sign in
Taking people in PolandPhase 2

Long-term study of IMVT-1402 in adults with Graves' disease

Tests IMVT-1402 over a longer period in adults with Graves' disease.

Key facts

Who runs it
Immunovant Sciences GmbH
Where
Bialystok, Bydgoszcz, Chorzow, Cracow, Gliwice, Kielce, Krakow, Lublin, Olsztyn, Opole, Poznan, Szczecin, Warsaw, and Wroclaw, PolandSee the 19 sitesAlso in 10 other countries, 84 sites
Registry title
A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease
Status
Recruiting
Phase
Phase 2
People taking part
128 people, planned
Started
11 Jun 2026
Expected to end
30 Mar 2030
Type of study
Interventional
Record updated
16 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Graves' disease who completed Study IMVT-1402-2502 or Study IMVT-1402-2503. It follows how well IMVT-1402 works over the long term.

Age
18 years and older
Sex
All sexes
Disease stage
Graves' disease (an overactive thyroid caused by the immune system)
Earlier treatment
People must have completed Study IMVT-1402-2502 or Study IMVT-1402-2503.

Main reasons for not taking part

  • Stopped the study drug for good during the treatment period of the earlier study
  • Met the stopping rules of the earlier study at any time while taking part in it

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Participants who completed Study IMVT-1402-2502 or Study IMVT-1402-2503

Who cannot take part

  • Have permanently discontinued IMP during the treatment period in the feeder study or have met study stopping criteria at any point up until the end of participation in the feeder study

Where in Poland

Also in 10 other countries, 84 sites

  • Uniwersytecki Szpital Kliniczny w BialymstokuBialystok, PolandTaking people
  • Centrum Medyczne INTERCOR Sp. z o.o.Bydgoszcz, PolandTaking people
  • Diab Serwis Popenda Sp. j.Chorzow, PolandTaking people
  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki W KrakowieCracow, PolandTaking people
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut BadawczyGliwice, PolandTaking people
  • Swietokrzyskie Centrum Onkologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej w KielcachKielce, PolandTaking people
  • Osrodek Medyczny OsteomedKrakow, PolandTaking people
  • Centrum Medyczne Hope Clinic Sebastian SzklenerLublin, PolandTaking people
  • Clinical Best Solutions Sp. z o.o. S.K.Lublin, PolandTaking people
  • Reumed Sp. z o.o.Lublin, PolandTaking people
  • Etyka Osrodek Badan Klinicznych Tomasz Pesta S.K.A.Olsztyn, PolandTaking people
  • Clinicly Sp. z o.o.Opole, PolandTaking people
  • Med Polonia Sp z o.o.Poznan, PolandTaking people
  • Uniwersyteckie Centrum Stomatologii i Medycyny Specjalistycznej Sp. z o.o.Poznan, PolandTaking people
  • Uniwersytecki Szpital Kliniczny Nr 1 Im. Prof. Tadeusza Sokolowskiego Pum W SzczecinieSzczecin, PolandTaking people
  • Eb Group Sp. z o.o.Warsaw, PolandTaking people
  • Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych i AdministracjiWarsaw, PolandTaking people
  • Trialmed Sp. z o.o.Warsaw, PolandTaking people
  • Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we WroclawiuWroclaw, PolandTaking people

About the trial

What the trial wants to find out

To evaluate the efficacy of IMVT-1402 as assessed by maintenance of euthyroidism, off ATD, and off IMVT-1402 for 52 weeks in Group A Participants

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease
Plain-language title
Long-term study of IMVT-1402 in adults with Graves' diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 17 November 2026.
Record updated
16 November 2026